Related Experiment Video
Updated: Jun 28, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Diabetes treatments
1University of Arkansas, 106 ASUP, Fayetteville, AR 72701, USA.
Journal of Gerontological Social Work
|October 18, 2008
Summary
This study reviews psychosocial interventions for older adults with diabetes, highlighting social work
Area of Science:
- Gerontology
- Endocrinology
- Social Work
Background:
- Rising global incidence of diabetes, particularly in aging populations, linked to inactivity and obesity.
- Diabetes management is often medication-focused, overlooking its significant biopsychosocial impact.
- Growing recognition of psychosocial factors in diabetes care necessitates tailored interventions.
Purpose of the Study:
- To systematically review psychosocial intervention studies for older adults with diabetes.
- To identify and summarize effective treatment protocols within this demographic.
- To highlight the role of social work in addressing the psychosocial needs of older adults with diabetes.
Main Methods:
- Systematic literature review of psychosocial intervention studies.
- Focus on interventions targeting older adults diagnosed with diabetes.
- Analysis of treatment protocols and reported outcomes.
Main Results:
- Identified a growing body of research on psychosocial interventions for older adults with diabetes.
- Summarized various treatment protocols, many aligning with social work practice.
- Demonstrated the potential for psychosocial interventions to improve holistic diabetes care.
Conclusions:
- Psychosocial interventions are crucial for comprehensive diabetes management in older adults.
- Social work practitioners are well-positioned to deliver these vital interventions.
- Further research and integration of psychosocial approaches are recommended for improved patient well-being.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...